SecBot SecBot
8-K ·Filed Jun 17, 2026

QURE

uniQure N.V.
BULLISH
Impact 8/10
Horizonweeks Processed5mo ago SEC0001104659-26-074853
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

The stock is likely to gap up significantly on this regulatory de-risking event. Traders should watch for potential capital raise announcements as the company prepares for BLA submission and confirmatory study costs. Key near-term catalysts: final Type B meeting minutes (expected within 30 days), BLA submission timing confirmation, and alignment on confirmatory study design.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$48.16
T+0 close · Jun 17, 2026 · via day close
Latest settled
−7.58%
T+60 · $44.51
Vs SPY
−10.73%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 17 $48.16entry
  2. T+1 · 5mo ago −3.88%α −4.66% · $46.29
  3. T+5 · 5mo ago +1.43%α +2.47% · $48.85
  4. T+20 · 4mo ago −18.27%α −19.59% · $39.36
  5. T+60 · 2mo ago −7.58%α −10.73% · $44.51
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

uniQure announced that the FDA has agreed the 3-year analysis from the Phase I/II study of AMT-130 in Huntington's disease can serve as the primary basis of a BLA for accelerated approval. The company intends to submit the BLA in Q3 2026. This is a major regulatory milestone for a gene therapy targeting a currently untreatable neurodegenerative disease with no approved disease-modifying therapies, de-risking the path to market for a pivotal pipeline asset.

Key Facts

  • FDA communicated during a Type B meeting that 3-year Phase I/II data are acceptable as primary basis for BLA for accelerated approval of AMT-130 in Huntington's disease.
  • Company plans to submit the BLA in the third quarter of 2026.
  • FDA seeks alignment on confirmatory study design prior to BLA submission, including consideration of a concurrent standard-of-care control instead of a sham procedure.
  • AMT-130 has RMAT, Breakthrough Therapy, and Fast Track designations from the FDA.
  • No approved therapies exist to delay onset or slow progression of Huntington's disease.

Financial Impact

FDA acceptance of Phase I/II data for BLA submission is a transformative regulatory catalyst for a pre-commercial biotech with a $1.7B market cap. Commercial opportunity in a ~75,000-patient addressable population with no approved disease-modifying therapies. Successful accelerated approval would unlock a multi-billion-dollar peak sales opportunity.

pipeline_valuationmarket_cap

Risk Factors

  • FDA could ultimately conclude data are insufficient to support BLA or accelerated approval after reviewing the complete application.
  • Confirmatory study design alignment and execution delays could push timeline.
  • Company may need to raise additional capital to fund BLA submission, manufacturing, and confirmatory study.
  • Longer-term post-approval requirements could be costly or difficult to satisfy.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
76% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-074853
Document: tm2618105d1_ex99-1.htm0001104659-26-074853
Document: 0001104659-26-074853-index-headers.html0001104659-26-074853
Document: 0001104659-26-074853-index.html0001104659-26-074853
Document: 0001104659-26-074853.txt0001104659-26-074853

Track record

38 reports on QURE

Performance horizon

6 of 10 bullish or bearish reports moved the stock their way by T+1. Best: +27.15% at T+20 after the Jul 29, 2026 report. 7 of 10 went positive at some point.

Filters
  1. Nov 6, 202610d ago 144 Neutral 2/10 Entry $22.79 to $22.71 Now $21.88 −3.99% ▼ −0.35% +0.02% vs SPY
  2. Nov 4, 202612d ago 8-K Bullish 7/10 No price data
  3. Nov 4, 202612d ago Press Release Neutral 6/10 Entry $23.03 to $21.01 Now $21.88 −4.99% ▼ −8.77% −4.36% vs SPY
  4. Nov 2, 202614d ago 8-K Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
  5. Nov 2, 202614d ago Press Release Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
  6. Oct 16, 20264w ago SC 13G/A Neutral 3/10 Entry $21.78 to $22.20 Now $21.88 +0.46% ▲ +1.93% +1.51% vs SPY
  7. Sep 2, 202610w ago 8-K Bullish 7/10 Entry $46.23 to $44.86 Now $21.88 −52.67% ▼ −2.96% −4.01% vs SPY
  8. Jul 29, 202615w ago 8-K Bullish 8/10 Entry $40.07 to $42.19 Now $21.88 −45.40% ▲ +5.29% +3.61% vs SPY
  9. Jul 7, 202619w ago Insider Cluster Bearish 5/10 Entry $41.41 to $43.49 Now $21.88 +47.16% ▼ −5.02% −5.33% vs SPY
  10. Jul 2, 202619w ago Insider Cluster Bearish 4/10 Entry $41.81 to $41.36 Now $21.88 +47.67% ▲ +1.08% +1.95% vs SPY
Showing 10 of 38

US Market Status

Market Closed · Opens in 8h 49m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 17, 2026